We chose to derive our meta-signature in lung cancer because lung adenocarcinoma is known to be RAS-driven with about a 30% KRAS mutation rate, but also has 26% of patients that are RAS pathway wild type (no genetic alterations on any of the broader RAS pathway members), thus presenting a potentially wide RAS-activity dynamic range. The gene discussed is KRAS; the disease is lung carcinoma.